PUBLISHER: The Business Research Company | PRODUCT CODE: 1596065
PUBLISHER: The Business Research Company | PRODUCT CODE: 1596065
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and Cas (CRISPR-associated) genes form part of a bacterial immune system that protects against viruses and foreign genetic elements. CRISPR refers to sequences of deoxyribonucleic acid (DNA) that contain short, repetitive segments, which bacteria use to store snippets of viral DNA after an infection. If the bacteria encounter the same virus again, they can recognize it based on these stored sequences. Cas genes encode proteins (like Cas9) that act as molecular scissors. These proteins can cut DNA at specific sites guided by RNA molecules (gRNA), which are transcribed from the CRISPR sequences. This mechanism allows precise gene editing and has revolutionized genetic research, enabling scientists to alter DNA in plants, animals and humans with high accuracy.
The CRISPR and Cas gene market consists of sales, by entities (organizations, sole traders and partnerships), of gene-editing tools and technologies used for precise DNA modifications.
The global CRISPR and CAS gene market was valued at $1,297.36 million in 2018 which grew till 2023 at a compound annual growth rate (CAGR) of more than 20.0%.
Growing Interest In Personalized Medicine
Growing interest in personalized medicine propelled the growth of the CRISPR and CAS gene market. Personalized medicine, also known as precision medicine or individualized medicine, is an approach to medical care that aims to tailor treatments and interventions to the specific characteristics of each patient. Personalized medicine drives demand for precise genetic therapies, focusing on treatments tailored to an individual's genetic profile. CRISPR technology enables targeted gene editing to address these variations, leading to increased investment in CRISPR-based therapies. This has accelerated its adoption for treating genetic disorders, cancer and other conditions in healthcare. For instance, in October 2022, according to the Personalized Medicine Coalition, a US-based organization that represents scientists, patients and providers, promoting the understanding and adoption of personalized medicine to benefit patients and the healthcare system, more than 75,000 genetic testing products and 300 personalized medicines were present on the market for people with multiple types of cancers, genetic rare diseases and a range of chronic and infectious diseases. Additionally, personalized medicines accounted for 34% of new drug approvals by the US Food and Drug Administration in 2022 and have accounted for at least 25% of approvals in each of the previous eight years. Therefore, growing interest in personalized medicine supported the growth of the CRISPR and CAS gene market during the historic period.
Advanced Gene Editing Tools To Revolutionize Personalized Medicine Through Precise Genetic Modifications
Major companies in the CRISPR and Cas gene market are focusing on developing advanced gene editing tools to enhance personalized medicine through precise genetic modifications. These tools enable targeted treatments tailored to an individual's genetic profile, addressing conditions like genetic disorders, cancer and rare diseases. By modifying specific genes responsible for disease progression, CRISPR technologies offer more effective therapies, improving patient outcomes and minimizing risks compared to traditional treatments, marking a significant advancement in precision medicine. For example, in May 2024, Profluent, a US-based AI-first protein design company, released the sequence of OpenCRISPR-1, a novel Cas9 gene editor with improved off-target editing created through Profluent's artificial intelligence (AI), using large language model trained on a database of 5.1 million Cas9-like proteins. This open-source project has the potential to revolutionize CRISPR treatment options by leveraging AI to develop new gene-editing reagents, marking a significant step forward in precision medicine.
The global CRISPR and Cas gene market is highly concentrated, with large players operating in the market. The top ten competitors in the market made up to 70.11% of the total market in 2023.
CRISPR And Cas Gene Global Market Opportunities And Strategies To 2033 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global CRISPR and Cas gene market as it emerges from the COVID-19 shut down.
Where is the largest and fastest-growing market for CRISPR and Cas gene? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The CRISPR and Cas gene market global report from The Business Research Company answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider CRISPR and Cas gene market; and compares it with other markets.